One in five pregnant women suffer from a mental health problem during pregnancy, according to BlueSkeye AI’s CEO. Image credit: Shutterstock/Nicoleta Ionescu.

The Medical and Healthcare products Regulatory Agency (MHRA) has greenlit BlueSkeye AI to begin a clinical trial investigating its TrueBlue mental health app for women at various stages of pregnancy.

The trial, which is being conducted in partnership with the UK’s Institute of Mental Health, will establish the safety and efficacy of the app. It is slated to enrol 125 perinatal women through NHS hospitals and will begin in early 2024, lasting for 14 months, according to a 30 November press release.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BlueSkeye AI’s app uses artificial intelligence (AI) to scan the user’s face and analyse their voice to identify and monitor signs of depression. The trial will assess how useable the app is in real life and how well the technology correlates with standard clinical measures of depression.

BlueSkeye AI’s CEO Professor Michael Valstar said: “One in five pregnant women suffer from a mental health problem during their pregnancy and many struggle to access support. The cost of a lack of timely access to good quality perinatal mental health care costs the NHS £1.2bn and wider UK society £8.1bn a year.”

The initial phase of the study will involve 12 participants to establish safety; a follow-up will enrol a further 113 participants for additional data.

See Also:

The design of the trial includes tasks such as reading or speaking to the app, that patients will complete once each week. The app will monitor the patient’s face and voice during this and will assess depression with added data input from self-report health questionnaires.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The increased prevalence of health apps has meant monitoring symptoms remotely is becoming more common. Technologies such as BlueSkeye AI’s app, which gathers data in-house rather than using a connected sensor device, means patients who do not always have access to support or those living with stigmatised illnesses can access health care more quickly. Big tech players such as Apple have also launched their own mental health tracking platforms.

As with all emerging technologies, apps also come with their issues. Discussions usually centre around cybersecurity due to the wealth of personal data that health apps store. There have been notable data breaches in the healthcare sector this year, including one that affected America’s largest healthcare systems. There was also the unveiling that millions of NHS medical devices in operation across England are unprotected against cybercrime, following a freedom of information request.

BlueSkeye AI encrypts users’ personal information using algorithms and says it is GDPR compliant, according to the company’s website.